What is Vorinostat?

Category: Prescription Drugs

Most popular types: Zolinza


See also: Bortezomib-vorinostat

Vorinostat is an anti-cancer agent used for the treatment of progressive, persistent, or recurrent cutaneous T-cell lymphoma (CTCL).

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 1
None 0

Commonly reported side effects and conditions associated with Vorinostat

Side effect Patients Percentage
Fatigue 1
Metallic taste in mouth 1
Nausea 1

Why patients stopped taking Vorinostat

Multiple reasons could be selected

Reason Patients Percentage
Doctor's advice 1
See 1 patient who's stopped taking Vorinostat


Stopped taking Vorinostat

Duration Patients Percentage
2 - 5 years 1
Adherence Evaluations Percentage
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 1
< $25 0
Not specified 0

What people switch to and from

Patients started taking Vorinostat after stopping:

Treatment Patients Percentage
Bexarotene (Targretin) 1

Patients stopped taking Vorinostat and switched to:

Treatment Patients Percentage
Doxorubicin (Adriamycin) 1
Last updated:
There are no evaluations for Vorinostat.